NanoSyrinx, a synthetic biology company developing a novel platform for targeted intracellular delivery of biologic therapeutics, today announced Anthony Johnson, MD, has joined its board as a non-executive director. Tony’s appointment forms part of the company’s ongoing strategy to expand and strengthen the company’s leadership team as the company prepares for its next phase of growth.
Most recently, Tony held the position of Chief Executive Officer at Goldfinch Bio and Chairman of the Board of Directors of Outran Therapeutics. He is a qualified physician with over 20 years of experience in senior and executive positions in early stage biotech and pharma companies, including Senior Vice President of Early Clinical Development at AstraZeneca and similar roles at Bristol-Myers Squibb and GlaxoSmithKline. In addition, Tony has experience in biotech fundraising and as a venture partner at OrbiMed Advisors. He holds an MBBS and MD (Research) from the University of New South Wales and an MPH in Epidemiology and Biostatistics from the University of Queensland.
Tony brings extensive and extensive expertise to NanoSyrinx, particularly in drug discovery and early clinical development. His appointment to the board will help the executive team further develop the company’s technology platform, to realize the full potential of intracellular medicine advances. The platform is based on naturally occurring ‘nanosyringes’ designed to selectively deliver peptide and protein payloads – including functional gene editing enzymes and nucleases – directly into the cytosol of target cells. This approach aims to unlock a pipeline of previously ‘unassailable’ targets for drug development.
“Tony’s experience as a results-driven pharmaceutical executive with extensive industry involvement, including biotech fundraising, will be invaluable as we build momentum into the next phase of the company’s development. In addition to the current members of the board. Steve Taylor and Dr. At Jane Dancer, our team is in a great position to drive this growth.”
Dr. Joe Healy, CEO, Nano Syrinx
Anthony Johnson, MD, Non-Executive Director, NanoSyrinx commented: “Based on more than a decade of fundamental research, NanoSyrinx is developing a truly unique and exciting platform technology to address a wide range of unmet medical needs for targeted intracellular delivery of biological molecules. . . , the company has built an excellent team and I look forward to working with them, leveraging both my interests and expertise in this field, to help advance technology and deliver safe and effective medicines for patients.”